These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 12036347)

  • 21. Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors.
    Kalra S; Joshi G; Munshi A; Kumar R
    Eur J Med Chem; 2017 Dec; 142():424-458. PubMed ID: 28911822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
    Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
    ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CDK versus GSK-3 inhibition: a purple haze no longer?
    Fischer PM
    Chem Biol; 2003 Dec; 10(12):1144-6. PubMed ID: 14700620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemical inhibitors of cyclin-dependent kinases: insights into design from X-ray crystallographic studies.
    Noble ME; Endicott JA
    Pharmacol Ther; 1999; 82(2-3):269-78. PubMed ID: 10454204
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The structure-based design of ATP-site directed protein kinase inhibitors.
    Toledo LM; Lydon NB; Elbaum D
    Curr Med Chem; 1999 Sep; 6(9):775-805. PubMed ID: 10495352
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel computational analysis of ligand-induced conformational changes in the ATP binding sites of cyclin dependent kinases.
    Subramanian J; Sharma S; B-Rao C
    J Med Chem; 2006 Sep; 49(18):5434-41. PubMed ID: 16942017
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alternative binding modes of an inhibitor to two different kinases.
    De Moliner E; Brown NR; Johnson LN
    Eur J Biochem; 2003 Aug; 270(15):3174-81. PubMed ID: 12869192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combinatorial ligand design targeted at protein families.
    Todorov NP; Buenemann CL; Alberts IL
    J Chem Inf Model; 2005; 45(2):314-20. PubMed ID: 15807493
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations.
    Chohan TA; Chen JJ; Qian HY; Pan YL; Chen JZ
    Mol Biosyst; 2016 Apr; 12(4):1250-68. PubMed ID: 26883408
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DrugScore meets CoMFA: adaptation of fields for molecular comparison (AFMoC) or how to tailor knowledge-based pair-potentials to a particular protein.
    Gohlke H; Klebe G
    J Med Chem; 2002 Sep; 45(19):4153-70. PubMed ID: 12213058
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles.
    Arris CE; Boyle FT; Calvert AH; Curtin NJ; Endicott JA; Garman EF; Gibson AE; Golding BT; Grant S; Griffin RJ; Jewsbury P; Johnson LN; Lawrie AM; Newell DR; Noble ME; Sausville EA; Schultz R; Yu W
    J Med Chem; 2000 Jul; 43(15):2797-804. PubMed ID: 10956187
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Receptor-guided alignment-based comparative 3D-QSAR studies of benzylidene malonitrile tyrphostins as EGFR and HER-2 kinase inhibitors.
    Kamath S; Buolamwini JK
    J Med Chem; 2003 Oct; 46(22):4657-68. PubMed ID: 14561085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis.
    Pirard B; Matter H
    J Med Chem; 2006 Jan; 49(1):51-69. PubMed ID: 16392792
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutants of protein kinase A that mimic the ATP-binding site of Aurora kinase.
    Pflug A; de Oliveira TM; Bossemeyer D; Engh RA
    Biochem J; 2011 Nov; 440(1):85-93. PubMed ID: 21774789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Visually interpretable models of kinase selectivity related features derived from field-based proteochemometrics.
    Subramanian V; Prusis P; Pietilä LO; Xhaard H; Wohlfahrt G
    J Chem Inf Model; 2013 Nov; 53(11):3021-30. PubMed ID: 24116714
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Purine analogs as CDK enzyme inhibitory agents: a survey and QSAR analysis.
    Lee AD; Ren S; Lien EJ
    Prog Drug Res; 2001; 56():155-93. PubMed ID: 11417113
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanism of CDK5/p25 binding by CDK inhibitors.
    Mapelli M; Massimiliano L; Crovace C; Seeliger MA; Tsai LH; Meijer L; Musacchio A
    J Med Chem; 2005 Feb; 48(3):671-9. PubMed ID: 15689152
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protein-Protein Interaction for the De Novo Design of Cyclin-Dependent Kinase Peptide Inhibitors.
    Arumugasamy K; Tripathi SK; Singh P; Singh SK
    Methods Mol Biol; 2016; 1336():59-66. PubMed ID: 26231708
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design and quantitative structure-activity relationship of 3-amidinobenzyl-1H-indole-2-carboxamides as potent, nonchiral, and selective inhibitors of blood coagulation factor Xa.
    Matter H; Defossa E; Heinelt U; Blohm PM; Schneider D; Müller A; Herok S; Schreuder H; Liesum A; Brachvogel V; Lönze P; Walser A; Al-Obeidi F; Wildgoose P
    J Med Chem; 2002 Jun; 45(13):2749-69. PubMed ID: 12061878
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemometrical classification of ephrin ligands and Eph kinases using GRID/CPCA approach.
    Myshkin E; Wang B
    J Chem Inf Comput Sci; 2003; 43(3):1004-10. PubMed ID: 12767159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.